JP5567048B2 - モルフィナン化合物 - Google Patents
モルフィナン化合物 Download PDFInfo
- Publication number
- JP5567048B2 JP5567048B2 JP2012043355A JP2012043355A JP5567048B2 JP 5567048 B2 JP5567048 B2 JP 5567048B2 JP 2012043355 A JP2012043355 A JP 2012043355A JP 2012043355 A JP2012043355 A JP 2012043355A JP 5567048 B2 JP5567048 B2 JP 5567048B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- pain
- disease
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/28—Morphinans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
Description
本出願は、35 U.S.C. §119のもとで、米国仮特許出願Nos.60/915,130、2007年5月1日出願;60/916,662、2007年5月8日出願;および60/976,004、2007年9月28日出願に基づく優先権を主張し、それらの内容全体をすべて本明細書に援用する。
用語“改善する”および“処置する”は互換性をもって用いられ、治療処置および/または予防処置を含む。両用語とも、疾患(たとえば本明細書に記載する疾患または障害)の発現または進行を低下、抑制、軽減、減少、制止、または安定化することを意味する。
本発明は、式Iの化合物を提供し、これにはその医薬的に許容できる塩類、溶媒和物および水和物が含まれる:
R1は、CH3、CH2D、CHD2、CD3、CHF2、およびCF3から選択され;
R2は、CH3、CH2D、CHD2、およびCD3から選択される。
ある態様において、R1がCH3である場合はR2はCH3またはCD3ではない。他の態様において、R1がCD3である場合はR2はCH3ではない。
式Iの化合物を合成するための好都合な方法は、デキストロメトルファンの製造に用いる合成法において、適切なジュウテリウム化された中間体および試薬を代わりに用いる。式Iの化合物は、下記に示す既知の中間体X、XIおよびXIIのいずれか1つから、および既知の方法で容易に入手できる関連中間体から製造できる。
本発明は、発熱物質を含まない組成物であって、有効量の式I(たとえば、本明細書中のいずれかの式を含む)の化合物、またはその化合物の医薬的に許容できる塩、溶媒和物もしくは水和物;および許容できるキャリヤーを含む組成物をも提供する。好ましくは、本発明の組成物は医薬用として配合され(“医薬組成物”)、その際、キャリヤーは医薬的に許容できるキャリヤーである。キャリヤー(1以上)は、配合物の他の成分と適合性であり、かつ医薬的に許容できるキャリヤーの場合には医薬中に使用する量でレシピエントに対して有害でないという意味で、“許容できる”。
他の態様において、本発明は、細胞におけるσ2受容体、N−メチル−D−アスパラギン酸(NDMA)の活性、またはα3β4ニコチン酸受容体の活性を調節する方法であって、細胞を1種類以上の式Iの化合物と接触させることを含む方法を提供する。
本発明の化合物および組成物は、溶液または生体試料(たとえば血漿)中のデキストロメトルファンの濃度を測定する方法、デキストロメトルファンの代謝を調べる方法、および他の分析試験における、試薬としても有用である。
a)既知濃度の式Iの化合物を溶液または生体試料に添加し;
b)デキストロメトルファンを式Iの化合物から識別する測定機器に溶液または生体試料を装入し;
c)式Iの化合物の検出量が生体試料または溶液に添加した式Iの化合物の既知濃度と相関するように測定機器を校正し;そして
d)校正した測定機器で生体試料中のデキストロメトルファンの量を測定し;そして
e)検出量と式Iの化合物について得られた濃度との相関関係を用いて溶液または生体試料中のデキストロメトルファンの濃度を判定する。
a)既知量の式Iの化合物を溶液または生体試料に添加し;
b)式Iの化合物についての少なくとも1つの信号およびデキストロメトルファンについての少なくとも1つの信号を、これら2種類の化合物を識別しうる測定機器で検出し;
c)式Iの化合物についての少なくとも1つの信号と溶液または生体試料に添加した式Iの化合物の既知量との相関関係を求め;そして
d)式Iの化合物について検出した少なくとも1つの信号と溶液または生体試料に添加した式Iの化合物の量との相関関係を用いて溶液または生体試料中のデキストロメトルファンの量を判定する。
* 各被験品を2mg/mLの濃度に溶解し、1mg/kgで投与した
** 配合物は、D5W中の10%ジメチルイソソルビド(DMI)、15%エタノール(ETOH)、35%プロピレングリコール(PG)(v:v:v)からなる
Claims (18)
- 情動不安定;自閉症;神経障害;神経変性疾患;脳傷害;意識異常障害;心血管疾患;緑内障;遅発性ジスキネジー;糖尿病性神経障害;網膜障害性疾患;ホモシステイン誘発性アポトーシスにより起きる疾患または障害;ホモシステインレベルの上昇により起きる疾患または障害;慢性疼痛;難治性疼痛;交感神経仲介疼痛;消化器機能障害に関連する疼痛;てんかん性発作;耳鳴;性的機能障害;難治性咳;皮膚炎;耽溺性障害;レット症候群(RTT);喉頭筋痙攣の無調節による音声障害;メトトレキセート神経毒性;および癌により起きる疲労から選択される疾患または状態の処置において使用する医薬組成物であって、
a.式Iの化合物:
[式中:
R1は、CD3であり;
R2は、CH3、およびCD3から選択される];および
b.医薬的に許容できるキャリヤーを含んでなり、医薬投与のために製剤されている前記医薬組成物。 - さらに、情動不安定;自閉症;神経障害;神経変性疾患;脳傷害;意識異常障害;心血管疾患;緑内障;遅発性ジスキネジー;糖尿病性神経障害;網膜障害性疾患;ホモシステイン誘発性アポトーシスにより起きる疾患または障害;ホモシステインレベルの上昇により起きる疾患または障害;慢性疼痛;難治性疼痛;糖尿病性神経障害性疼痛;交感神経仲介疼痛;消化器機能障害に関連する疼痛;てんかん性発作;耳鳴;性的機能障害;難治性咳;皮膚炎;耽溺性障害;レット症候群(RTT);喉頭筋痙攣の無調節による音声障害;メトトレキセート神経毒性;および癌により起きる疲労から選択される疾患または状態の治療または予防に有用な第2の療法薬を含む、請求項1または2に記載の組成物。
- 疾患または状態が糖尿病性神経障害性疼痛である、請求項3に記載の組成物。
- 第2の療法薬が、キニジンまたはその塩、オキシコドン、およびガバペンチンから選択される、請求項3に記載の組成物。
- 第2の療法薬が、キニジンまたはその塩である、請求項5に記載の組成物。
- 第2の療法薬が硫酸キニジンである、請求項6に記載の組成物。
- 式Iの化合物の医薬的に許容できる塩がHBr塩である、請求項1〜7のいずれか1項に記載の組成物。
- ジュウテリウムとして指定されていない原子はいずれもそれの自然界での同位体存在率で存在する、請求項1〜8のいずれか1項に記載の組成物。
- 情動不安定;自閉症;神経障害;神経変性疾患;脳傷害;意識異常障害;心血管疾患;緑内障;遅発性ジスキネジー;糖尿病性神経障害;網膜障害性疾患;ホモシステイン誘発性アポトーシスにより起きる疾患または障害;ホモシステインレベルの上昇により起きる疾患または障害;慢性疼痛;難治性疼痛;交感神経仲介疼痛;消化器機能障害に関連する疼痛;てんかん性発作;耳鳴;性的機能障害;難治性咳;皮膚炎;耽溺性障害;レット症候群(RTT);喉頭筋痙攣の無調節による音声障害;メトトレキセート神経毒性;および癌により起きる疲労から選択される疾患または状態の処置において使用する医薬の調製における、式Iの化合物:
[式中:
R1は、CD3であり;
R2は、CH3、およびCD3から選択される]の使用。 - 医薬が、情動不安定;自閉症;神経障害;神経変性疾患;脳傷害;意識異常障害;心血管疾患;緑内障;遅発性ジスキネジー;糖尿病性神経障害;網膜障害性疾患;ホモシステイン誘発性アポトーシスにより起きる疾患または障害;ホモシステインレベルの上昇により起きる疾患または障害;慢性疼痛;難治性疼痛;糖尿病性神経障害性疼痛;交感神経仲介疼痛;消化器機能障害に関連する疼痛;てんかん性発作;耳鳴;性的機能障害;難治性咳;皮膚炎;耽溺性障害;レット症候群(RTT);喉頭筋痙攣の無調節による音声障害;メトトレキセート神経毒性;および癌により起きる疲労から選択される疾患または状態の治療または予防に有用な第2の療法薬をさらに含む、請求項10または11に記載の使用。
- 疾患または状態が糖尿病性神経障害性疼痛である、請求項12に記載の使用。
- 第2の療法薬が、キニジンまたはその塩、オキシコドン、およびガバペンチンから選択される、請求項12に記載の使用。
- 第2の療法薬が、キニジンまたはその塩である、請求項14に記載の使用。
- 第2の療法薬が硫酸キニジンである、請求項15に記載の使用。
- 式Iの化合物の医薬的に許容できる塩がHBr塩である、請求項10〜16のいずれか1項に記載の使用。
- ジュウテリウムとして指定されていない原子はいずれもそれの自然界での同位体存在率で存在する、請求項10〜17のいずれか1項に記載の使用。
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91513007P | 2007-05-01 | 2007-05-01 | |
US60/915,130 | 2007-05-01 | ||
US91666207P | 2007-05-08 | 2007-05-08 | |
US60/916,662 | 2007-05-08 | ||
US97600407P | 2007-09-28 | 2007-09-28 | |
US60/976,004 | 2007-09-28 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010506617A Division JP4944244B2 (ja) | 2007-05-01 | 2008-04-30 | モルフィナン化合物 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014124972A Division JP5968953B2 (ja) | 2007-05-01 | 2014-06-18 | モルフィナン化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012131815A JP2012131815A (ja) | 2012-07-12 |
JP5567048B2 true JP5567048B2 (ja) | 2014-08-06 |
Family
ID=47290415
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010506617A Active JP4944244B2 (ja) | 2007-05-01 | 2008-04-30 | モルフィナン化合物 |
JP2012043355A Active JP5567048B2 (ja) | 2007-05-01 | 2012-02-29 | モルフィナン化合物 |
JP2014124972A Active JP5968953B2 (ja) | 2007-05-01 | 2014-06-18 | モルフィナン化合物 |
JP2016134199A Active JP6316881B2 (ja) | 2007-05-01 | 2016-07-06 | モルフィナン化合物 |
JP2018061642A Pending JP2018115199A (ja) | 2007-05-01 | 2018-03-28 | モルフィナン化合物 |
JP2019232665A Active JP6864070B2 (ja) | 2007-05-01 | 2019-12-24 | モルフィナン化合物 |
JP2021063101A Active JP7177881B2 (ja) | 2007-05-01 | 2021-04-01 | モルフィナン化合物 |
JP2022181010A Pending JP2023017963A (ja) | 2007-05-01 | 2022-11-11 | モルフィナン化合物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010506617A Active JP4944244B2 (ja) | 2007-05-01 | 2008-04-30 | モルフィナン化合物 |
Family Applications After (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014124972A Active JP5968953B2 (ja) | 2007-05-01 | 2014-06-18 | モルフィナン化合物 |
JP2016134199A Active JP6316881B2 (ja) | 2007-05-01 | 2016-07-06 | モルフィナン化合物 |
JP2018061642A Pending JP2018115199A (ja) | 2007-05-01 | 2018-03-28 | モルフィナン化合物 |
JP2019232665A Active JP6864070B2 (ja) | 2007-05-01 | 2019-12-24 | モルフィナン化合物 |
JP2021063101A Active JP7177881B2 (ja) | 2007-05-01 | 2021-04-01 | モルフィナン化合物 |
JP2022181010A Pending JP2023017963A (ja) | 2007-05-01 | 2022-11-11 | モルフィナン化合物 |
Country Status (15)
Country | Link |
---|---|
US (5) | US7973049B2 (ja) |
EP (4) | EP2152709B1 (ja) |
JP (8) | JP4944244B2 (ja) |
CN (3) | CN101687868B (ja) |
AT (1) | ATE546449T1 (ja) |
AU (1) | AU2008247818B2 (ja) |
CA (2) | CA2685723C (ja) |
DK (3) | DK2345653T3 (ja) |
ES (2) | ES2401892T3 (ja) |
HK (3) | HK1155441A1 (ja) |
HR (2) | HRP20120317T1 (ja) |
MX (3) | MX370608B (ja) |
PL (4) | PL2345653T3 (ja) |
PT (2) | PT2152709E (ja) |
WO (1) | WO2008137474A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014196331A (ja) * | 2007-05-01 | 2014-10-16 | コンサート ファーマシューティカルズ インコーポレイテッド | モルフィナン化合物 |
Families Citing this family (174)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010501011A (ja) * | 2006-08-16 | 2010-01-14 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | オピオイド鎮痛薬の調製および効用 |
EP2357183B1 (en) * | 2007-05-01 | 2015-07-01 | Concert Pharmaceuticals Inc. | Morphinan compounds |
DK3248978T3 (da) * | 2008-09-19 | 2019-11-18 | Concert Pharmaceuticals Inc | Deutererede morphinanforbindelser |
PL2397158T3 (pl) * | 2008-10-30 | 2016-09-30 | Skojarzone podawanie związków morfinanów oraz leków przeciwdepresyjnych w leczeniu nietrzymania afektu | |
WO2011009020A2 (en) | 2009-07-16 | 2011-01-20 | Mallinckrodt Inc. | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers |
US20110206780A1 (en) * | 2010-01-06 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Morphinan modulators of nmda receptors, sigma1 receptors, sigma2 receptors, and/or a3b4 nicotinic receptors |
CN102762554A (zh) | 2010-02-16 | 2012-10-31 | 辉瑞大药厂 | 5-ht4受体的部分激动剂(r)-4-((4-((4-(四氢呋喃-3-基氧基)苯并[d]异*唑-3-基氧基)甲基)哌啶-1-基)甲基)四氢-2h-吡喃-4-醇 |
JP2014525413A (ja) | 2011-08-26 | 2014-09-29 | ハインリッヒ−ハイネ−ウニベルジテート デュッセルドルフ | 糖尿病および関連障害を治療するためのモルフィナン誘導体 |
EP2561866A1 (en) * | 2011-08-26 | 2013-02-27 | Heinrich-Heine-Universität Düsseldorf | Morphinan-derivatives for treating diabetes and related disorders |
WO2014037832A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of epilepsy and neurological diseases |
WO2013167990A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of depression |
US9738631B2 (en) | 2012-05-07 | 2017-08-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
JP2015522531A (ja) | 2012-05-07 | 2015-08-06 | セリックスビオ プライヴェート リミテッド | 神経筋疾患及び神経変性疾患の治療のための組成物及び方法 |
US9403826B2 (en) | 2012-05-08 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory disorders |
WO2013168023A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of parkinson's disease |
WO2013167993A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological degenerative disorders |
US9522884B2 (en) | 2012-05-08 | 2016-12-20 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic disorders |
US9309233B2 (en) | 2012-05-08 | 2016-04-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of blood clotting disorders |
US9233161B2 (en) | 2012-05-10 | 2016-01-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological conditions |
US9403857B2 (en) | 2012-05-10 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
WO2013168015A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of asthma and allergy |
US9321775B2 (en) | 2012-05-10 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of moderate to severe pain |
US9346742B2 (en) | 2012-05-10 | 2016-05-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of fibromyalgia pain |
US9573927B2 (en) | 2012-05-10 | 2017-02-21 | Cellix Bio Private Limited | Compositions and methods for the treatment of severe pain |
US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
WO2013167999A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurologic diseases |
US9315478B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
WO2013168005A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
US9273061B2 (en) | 2012-05-10 | 2016-03-01 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
WO2013168014A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of familial amyloid polyneuropathy |
WO2013168033A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of neurologic diseases |
CN104603097A (zh) | 2012-05-23 | 2015-05-06 | 塞利克斯比奥私人有限公司 | 用于治疗多发性硬化症的组合物和方法 |
US9434729B2 (en) | 2012-05-23 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
CN104603100A (zh) | 2012-05-23 | 2015-05-06 | 塞利克斯比奥私人有限公司 | 用于治疗炎症性肠病的组合物和方法 |
WO2013175347A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
US9492409B2 (en) | 2012-05-23 | 2016-11-15 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9765020B2 (en) | 2012-05-23 | 2017-09-19 | Cellix Bio Private Limited | Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis |
US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
WO2014020480A2 (en) | 2012-08-03 | 2014-02-06 | Mahesh Kandula | Compositions and methods for the treatment migraine and neurologic diseases |
WO2014037833A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment inflammation and lipid disorders |
WO2014037834A2 (en) | 2012-09-08 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of inflammation and lipid disorders |
CN103044327B (zh) * | 2013-01-07 | 2014-12-17 | 苏州立新制药有限公司 | 一种右美沙芬的制备方法 |
CN105491885B (zh) * | 2013-03-07 | 2018-09-25 | 思想实验室有限责任公司 | 疼痛药物组合及其用途 |
HU231191B1 (hu) | 2013-04-15 | 2021-08-30 | Szegedi Tudományegyetem | Izotóp tartalmú morfin molekulák |
US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
WO2014195961A1 (en) | 2013-06-04 | 2014-12-11 | Mahesh Kandula | Compositions and methods for the treatment of diabetes and pre-diabetes |
US11285118B2 (en) | 2013-11-05 | 2022-03-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11058648B2 (en) | 2013-11-05 | 2021-07-13 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11478468B2 (en) | 2013-11-05 | 2022-10-25 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US20200261431A1 (en) | 2019-01-07 | 2020-08-20 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11382874B2 (en) | 2013-11-05 | 2022-07-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11197839B2 (en) | 2013-11-05 | 2021-12-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11207281B2 (en) | 2013-11-05 | 2021-12-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11510918B2 (en) | 2013-11-05 | 2022-11-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US20220233470A1 (en) | 2013-11-05 | 2022-07-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11229640B2 (en) | 2013-11-05 | 2022-01-25 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
US11291665B2 (en) | 2013-11-05 | 2022-04-05 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11123343B2 (en) | 2013-11-05 | 2021-09-21 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11439636B1 (en) | 2013-11-05 | 2022-09-13 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11426370B2 (en) | 2013-11-05 | 2022-08-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11497721B2 (en) | 2013-11-05 | 2022-11-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11617747B2 (en) | 2013-11-05 | 2023-04-04 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US20160361305A1 (en) | 2013-11-05 | 2016-12-15 | Antecip Bioventures Ii Llc | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
US10864209B2 (en) | 2013-11-05 | 2020-12-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10105327B2 (en) | 2013-11-05 | 2018-10-23 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects |
US20160324807A1 (en) | 2013-11-05 | 2016-11-10 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10105361B2 (en) | 2013-11-05 | 2018-10-23 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US9198905B2 (en) | 2013-11-05 | 2015-12-01 | Antecip Bioventures Ii Llc | Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects |
US11065248B2 (en) | 2013-11-05 | 2021-07-20 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US9408815B2 (en) | 2013-11-05 | 2016-08-09 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11571417B2 (en) | 2013-11-05 | 2023-02-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US9700528B2 (en) | 2013-11-05 | 2017-07-11 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US11364233B2 (en) | 2013-11-05 | 2022-06-21 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11541048B2 (en) | 2013-11-05 | 2023-01-03 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11571399B2 (en) | 2013-11-05 | 2023-02-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11291638B2 (en) | 2013-11-05 | 2022-04-05 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US9861595B2 (en) | 2013-11-05 | 2018-01-09 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US9707191B2 (en) | 2013-11-05 | 2017-07-18 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US10786469B2 (en) | 2013-11-05 | 2020-09-29 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US10881657B2 (en) | 2013-11-05 | 2021-01-05 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11273134B2 (en) | 2013-11-05 | 2022-03-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US9457025B2 (en) | 2013-11-05 | 2016-10-04 | Antecip Bioventures Ii Llc | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
US10894047B2 (en) | 2013-11-05 | 2021-01-19 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10512643B2 (en) | 2013-11-05 | 2019-12-24 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US10813924B2 (en) | 2018-03-20 | 2020-10-27 | Antecip Bioventures Ii Llc | Bupropion and dextromethorphan for treating nicotine addiction |
US11123344B2 (en) | 2013-11-05 | 2021-09-21 | Axsome Therapeutics, Inc. | Bupropion as a modulator of drug activity |
US11213521B2 (en) | 2013-11-05 | 2022-01-04 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US9867819B2 (en) | 2013-11-05 | 2018-01-16 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US11298352B2 (en) | 2013-11-05 | 2022-04-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10799497B2 (en) | 2013-11-05 | 2020-10-13 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
US11185515B2 (en) | 2013-11-05 | 2021-11-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US9402843B2 (en) | 2013-11-05 | 2016-08-02 | Antecip Bioventures Ii Llc | Compositions and methods of using threohydroxybupropion for therapeutic purposes |
US10874665B2 (en) | 2013-11-05 | 2020-12-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11020389B2 (en) | 2013-11-05 | 2021-06-01 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10966974B2 (en) | 2013-11-05 | 2021-04-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10980800B2 (en) | 2013-11-05 | 2021-04-20 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10874663B2 (en) | 2013-11-05 | 2020-12-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10688066B2 (en) | 2018-03-20 | 2020-06-23 | Antecip Bioventures Ii Llc | Bupropion and dextromethorphan for treating nicotine addiction |
US11096937B2 (en) | 2013-11-05 | 2021-08-24 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10966942B2 (en) | 2019-01-07 | 2021-04-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11191739B2 (en) | 2013-11-05 | 2021-12-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11129826B2 (en) | 2013-11-05 | 2021-09-28 | Axsome Therapeutics, Inc. | Bupropion as a modulator of drug activity |
US9763932B2 (en) | 2013-11-05 | 2017-09-19 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US11357744B2 (en) | 2013-11-05 | 2022-06-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11090300B2 (en) | 2013-11-05 | 2021-08-17 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11534414B2 (en) | 2013-11-05 | 2022-12-27 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11141416B2 (en) | 2013-11-05 | 2021-10-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10772850B2 (en) | 2013-11-05 | 2020-09-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11590124B2 (en) | 2013-11-05 | 2023-02-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11007189B2 (en) | 2013-11-05 | 2021-05-18 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11311534B2 (en) | 2013-11-05 | 2022-04-26 | Antecip Bio Ventures Ii Llc | Bupropion as a modulator of drug activity |
US11298351B2 (en) | 2013-11-05 | 2022-04-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11576909B2 (en) | 2013-11-05 | 2023-02-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11147808B2 (en) | 2013-11-05 | 2021-10-19 | Antecip Bioventures Ii Llc | Method of decreasing the fluctuation index of dextromethorphan |
US11253491B2 (en) | 2013-11-05 | 2022-02-22 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11253492B2 (en) | 2013-11-05 | 2022-02-22 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US9457023B1 (en) | 2013-11-05 | 2016-10-04 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US11285146B2 (en) | 2013-11-05 | 2022-03-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11419867B2 (en) | 2013-11-05 | 2022-08-23 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11426401B2 (en) | 2013-11-05 | 2022-08-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10966941B2 (en) | 2013-11-05 | 2021-04-06 | Antecip Bioventures Ii Llp | Bupropion as a modulator of drug activity |
US11517543B2 (en) | 2013-11-05 | 2022-12-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11234946B2 (en) | 2013-11-05 | 2022-02-01 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10945973B2 (en) | 2013-11-05 | 2021-03-16 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11596627B2 (en) | 2013-11-05 | 2023-03-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11433067B2 (en) | 2013-11-05 | 2022-09-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10874664B2 (en) | 2013-11-05 | 2020-12-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11273133B2 (en) | 2013-11-05 | 2022-03-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11344544B2 (en) | 2013-11-05 | 2022-05-31 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US9968568B2 (en) | 2013-11-05 | 2018-05-15 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US10898453B2 (en) | 2013-11-05 | 2021-01-26 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10940124B2 (en) | 2019-01-07 | 2021-03-09 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10894046B2 (en) | 2013-11-05 | 2021-01-19 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11576877B2 (en) | 2013-11-05 | 2023-02-14 | Antecip Bioventures Ii Llc | Bupropion as modulator of drug activity |
US11969421B2 (en) | 2013-11-05 | 2024-04-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10080727B2 (en) | 2013-11-05 | 2018-09-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US10933034B2 (en) | 2013-11-05 | 2021-03-02 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11617728B2 (en) | 2013-11-05 | 2023-04-04 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US20200338022A1 (en) | 2019-01-07 | 2020-10-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US9474731B1 (en) | 2013-11-05 | 2016-10-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US11541021B2 (en) | 2013-11-05 | 2023-01-03 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11524007B2 (en) | 2013-11-05 | 2022-12-13 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
AU2014348256B2 (en) * | 2013-11-18 | 2018-06-07 | SpecGx LLC | Preparation of normorphinans |
US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
CN103833635B (zh) * | 2014-03-20 | 2015-10-14 | 武汉药谷生物工程有限公司 | 一种安全有效的镇咳药磷酸二甲啡烷的制备方法 |
SG10201901242PA (en) * | 2014-09-14 | 2019-03-28 | Avanir Pharmaceuticals Inc | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia |
EP3240779B1 (en) | 2014-09-26 | 2020-10-28 | Cellixbio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
ES2799309T3 (es) | 2014-09-29 | 2020-12-16 | Cellix Bio Private Ltd | Compuestos y composiciones para el tratamiento de esclerosis múltiple |
EP3212626B1 (en) | 2014-10-27 | 2018-11-07 | Cellix Bio Private Limited | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
EP3242869B1 (en) | 2015-01-06 | 2021-10-27 | Cellixbio Private Limited | Compositions and methods for the treatment of inflammation and pain |
US20180296647A1 (en) | 2015-10-14 | 2018-10-18 | Kurume University | Prophylactic and therapeutic agent for rett syndrome (rtt) comprising ghrelin as active ingredient |
US10583171B2 (en) | 2015-11-30 | 2020-03-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | NMDAR antagonists for the treatment of diseases associated with angiogenesis |
US11376245B2 (en) * | 2016-06-13 | 2022-07-05 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Dizocilpine derivatives as peripheral NMDA receptor antagonists |
EP4122919A1 (en) | 2016-07-04 | 2023-01-25 | Avanir Pharmaceuticals, Inc. | Methods for the synthesis of deuterated dextromethorphan |
US11214545B2 (en) | 2017-09-07 | 2022-01-04 | Otsuka Pharmaceutical Co., Ltd. | Industrial process of mono-alkylating piperidine nitrogen in piperidine derivative with deuterated-lower-alkyl |
JP7148891B2 (ja) | 2018-10-12 | 2022-10-06 | 大同特殊鋼株式会社 | 圧粉磁心及びその製造方法 |
US10925842B2 (en) | 2019-01-07 | 2021-02-23 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US20220127206A1 (en) | 2019-03-13 | 2022-04-28 | Otsuka Pharmaceutical Co., Ltd. | Method for introducing deuterated lower alkyl into amine moiety of compound containing secondary amine |
EP4142729A1 (en) | 2020-04-27 | 2023-03-08 | Avanir Pharmaceuticals, Inc. | Methods of treating agitation associated with alzheimer's disease |
WO2022017300A1 (zh) | 2020-07-20 | 2022-01-27 | 深圳信立泰药业股份有限公司 | 一种药物组合物及其应用 |
CN115322150B (zh) * | 2021-05-11 | 2024-05-28 | 深圳信立泰药业股份有限公司 | 氘代右美沙芬氢溴酸盐的固体及其制备方法和医药用途 |
WO2023076414A1 (en) | 2021-10-27 | 2023-05-04 | Avanir Pharmaceuticals, Inc. | Methods of treating agitation associated with alzheimer's disease |
US11717518B1 (en) | 2022-06-30 | 2023-08-08 | Antecip Bioventures Ii Llc | Bupropion dosage forms with reduced food and alcohol dosing effects |
US11730706B1 (en) | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
CN117205214A (zh) * | 2023-09-14 | 2023-12-12 | 大连医科大学 | 右美沙芬在制备治疗溃疡性结肠炎的药物中的应用 |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB713146A (en) | 1951-10-18 | 1954-08-04 | Roche Products Ltd | Anti-cough agents comprising (ú½)-3-hydroxy-n-methyl-morphinane ethers and process for the manufacture thereof |
US4316888A (en) | 1980-04-15 | 1982-02-23 | Nelson Research & Development Co. | Method and composition of reducing pain |
US4446140A (en) | 1981-12-10 | 1984-05-01 | Nelson Research & Development Company | Method and composition for treating mouth pain |
JPS6089474A (ja) | 1983-10-20 | 1985-05-20 | Toyo Pharma- Kk | モルフイナン誘導体,その製造方法,及び該化合物を含有する抗腫瘍剤 |
US4694010A (en) | 1985-08-16 | 1987-09-15 | New York University | Anticonvulsant compositions and method |
US4898860A (en) | 1985-08-16 | 1990-02-06 | New York University | Anticonvulsant composition and method |
US4994467A (en) | 1989-05-31 | 1991-02-19 | Zimmerman Andrew W | Treating autism and other developmental disorders in children with NMDA receptor antagonists |
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
US5166207A (en) * | 1991-06-17 | 1992-11-24 | Neurotherapeutics, Inc. | Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders |
US5350756A (en) | 1991-06-17 | 1994-09-27 | Smith Richard A | Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan |
US5366980A (en) * | 1991-06-17 | 1994-11-22 | Smith Richard A | Use of dextromethorphan and an oxidase inhibitor to treat dermatitis |
US5336980A (en) | 1992-12-10 | 1994-08-09 | Leopold Kostal Gmbh & Co. | Apparatus and method for controlling a windshield wiping system |
US5716981A (en) | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
WO1995026325A2 (en) | 1994-03-25 | 1995-10-05 | Isotechnika Inc. | Enhancement of the efficacy of drugs by deuteration |
US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
WO1996009044A1 (en) | 1994-09-22 | 1996-03-28 | Richard Alan Smith | Compositions useful for the preparation of medicines for treating a variety of intractable disorders |
US5605911A (en) | 1995-01-31 | 1997-02-25 | Washington University | Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH) |
US6099562A (en) * | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
US6197830B1 (en) | 1995-09-22 | 2001-03-06 | Bruce M. Frome | Method for achieving relief from sympathetically mediated pain |
AUPN605795A0 (en) | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
CH690817A5 (de) | 1996-09-03 | 2001-01-31 | Flachsmann Ag Emil | Verfahren zur Herstellung eines stabilen, homogenen, von Folgeprodukten freien oder nahezu freien Extraktes. |
ES2297882T3 (es) * | 1997-03-27 | 2008-05-01 | Toray Industries, Inc. | Derivados de morfinano y usos medicos de los mismos. |
US6884429B2 (en) * | 1997-09-05 | 2005-04-26 | Isotechnika International Inc. | Medical devices incorporating deuterated rapamycin for controlled delivery thereof |
US6440710B1 (en) * | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
EP1104760B1 (en) * | 1999-12-03 | 2003-03-12 | Pfizer Products Inc. | Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents |
WO2001041707A2 (en) * | 1999-12-08 | 2001-06-14 | Vanderbilt University | Modulation of in vivo glutamine and glycine levels in the treatment of autism |
US20050129783A1 (en) | 2001-04-19 | 2005-06-16 | Mccleary Edward L. | Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health |
US6780871B2 (en) | 2001-01-29 | 2004-08-24 | Albany Medical College | Methods and compositions for treating addiction disorders |
US6583152B2 (en) | 2001-04-30 | 2003-06-24 | Dexgen Pharmaceuticals, Inc. | Composition for reducing the risk or progression of cardiovascular diseases |
US20040087479A1 (en) | 2001-04-30 | 2004-05-06 | Sosnowski Robert E. | Composition and method for reducing the risk or progression of cardiovascular, glaucoma, tardive dyskinesia and other diseases |
JP4101661B2 (ja) | 2001-05-03 | 2008-06-18 | エフ.ホフマン−ラ ロシュ アーゲー | 非晶質メシル酸ネルフィナビルの製薬剤形 |
EP1392262A1 (en) * | 2001-05-24 | 2004-03-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
TWI326214B (en) * | 2002-07-17 | 2010-06-21 | Avanir Pharmaceuticals Inc | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
TW200413273A (en) * | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
DE102004009445A1 (de) | 2004-02-27 | 2005-09-29 | Chemetall Gmbh | Verfahren zur Herstellung von Alkyllithiumverbindungen und Aryllithiumverbindungen durch Reaktionsverfolgung mittels IR-Spektroskopie |
EP1750710B1 (en) | 2004-05-14 | 2014-04-16 | KNU-Industry Cooperation Foundation | Neuroprotective properties of dextrorotatory morphinans |
MX2007003731A (es) * | 2004-09-29 | 2007-08-14 | Johnson & Johnson | Formas de dosis farmaceuticas de compuestos similares a rapamicina amorfos estables. |
US20070191411A1 (en) | 2004-10-07 | 2007-08-16 | Smith Richard A | Enhancement of impaired motor and mental functions, using dextromethorphan and oxidase enzyme inhibitor |
US7114547B2 (en) * | 2005-01-11 | 2006-10-03 | Sullivan Michael R | Casting ring |
JP4576287B2 (ja) * | 2005-05-12 | 2010-11-04 | ゲイツ・ユニッタ・アジア株式会社 | 帆布の供給方法、配合物付き帆布の製造方法、および動力伝達ベルトの製造方法 |
AR054583A1 (es) * | 2005-07-26 | 2007-06-27 | Altana Pharma Ag | Pantoprazol isotopicamente sustituido |
EA014432B1 (ru) * | 2005-07-29 | 2010-12-30 | Консерт Фармасьютикалс Инк. | Дейтерированные производные 1,3-бензодиоксола |
WO2007041630A1 (en) * | 2005-10-06 | 2007-04-12 | Auspex Pharmaceuticals, Inc. | Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties |
US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
JO2630B1 (en) | 2006-04-13 | 2012-06-17 | نوفارتيس ايه جي | Organic compounds |
JP2010501011A (ja) | 2006-08-16 | 2010-01-14 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | オピオイド鎮痛薬の調製および効用 |
CA2661404A1 (en) * | 2006-09-05 | 2008-03-13 | Schering Corporation | Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis |
WO2008097924A2 (en) | 2007-02-05 | 2008-08-14 | Avanir Pharmaceuticals | Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders |
US20080188714A1 (en) | 2007-02-07 | 2008-08-07 | Boston Scientific Scimed, Inc. | Electromechanical in-situ cleaning of optical elements |
MX370608B (es) | 2007-05-01 | 2019-12-18 | Concert Pharmaceuticals Inc | Compuestos de morfinano. |
DK3248978T3 (da) | 2008-09-19 | 2019-11-18 | Concert Pharmaceuticals Inc | Deutererede morphinanforbindelser |
PL2397158T3 (pl) | 2008-10-30 | 2016-09-30 | Skojarzone podawanie związków morfinanów oraz leków przeciwdepresyjnych w leczeniu nietrzymania afektu |
-
2008
- 2008-04-30 MX MX2016010275A patent/MX370608B/es unknown
- 2008-04-30 AU AU2008247818A patent/AU2008247818B2/en active Active
- 2008-04-30 DK DK11000763.0T patent/DK2345653T3/da active
- 2008-04-30 CA CA2685723A patent/CA2685723C/en active Active
- 2008-04-30 ES ES11000763T patent/ES2401892T3/es active Active
- 2008-04-30 CN CN2008800177682A patent/CN101687868B/zh active Active
- 2008-04-30 CN CN201210402412.9A patent/CN102964302B/zh active Active
- 2008-04-30 EP EP08747238A patent/EP2152709B1/en active Active
- 2008-04-30 PT PT08747238T patent/PT2152709E/pt unknown
- 2008-04-30 EP EP11000763A patent/EP2345653B1/en active Active
- 2008-04-30 US US12/112,936 patent/US7973049B2/en active Active
- 2008-04-30 DK DK12176476.5T patent/DK2522667T3/da active
- 2008-04-30 WO PCT/US2008/062089 patent/WO2008137474A1/en active Application Filing
- 2008-04-30 PL PL11000763T patent/PL2345653T3/pl unknown
- 2008-04-30 EP EP12176544.0A patent/EP2522668B1/en active Active
- 2008-04-30 MX MX2009011958A patent/MX2009011958A/es active IP Right Grant
- 2008-04-30 PL PL12176476T patent/PL2522667T3/pl unknown
- 2008-04-30 PT PT110007630T patent/PT2345653E/pt unknown
- 2008-04-30 AT AT08747238T patent/ATE546449T1/de active
- 2008-04-30 CN CN201210208158.9A patent/CN102718710B/zh active Active
- 2008-04-30 ES ES08747238T patent/ES2381317T3/es active Active
- 2008-04-30 CA CA2809739A patent/CA2809739C/en active Active
- 2008-04-30 PL PL12176544T patent/PL2522668T3/pl unknown
- 2008-04-30 EP EP12176476.5A patent/EP2522667B1/en active Active
- 2008-04-30 PL PL08747238T patent/PL2152709T3/pl unknown
- 2008-04-30 JP JP2010506617A patent/JP4944244B2/ja active Active
- 2008-04-30 DK DK08747238.7T patent/DK2152709T3/da active
-
2009
- 2009-11-03 MX MX2019006270A patent/MX2019006270A/es unknown
-
2010
- 2010-07-22 HK HK11109618.0A patent/HK1155441A1/xx unknown
- 2010-07-22 HK HK10107070.6A patent/HK1140755A1/xx unknown
-
2011
- 2011-05-31 US US13/118,912 patent/US8188110B2/en active Active
- 2011-05-31 US US13/118,935 patent/US8541436B2/en active Active
-
2012
- 2012-02-29 JP JP2012043355A patent/JP5567048B2/ja active Active
- 2012-04-11 HR HRP20120317AT patent/HRP20120317T1/hr unknown
-
2013
- 2013-03-11 HR HRP20130213AT patent/HRP20130213T1/hr unknown
- 2013-06-20 HK HK13107190.8A patent/HK1179961A1/zh unknown
- 2013-07-24 US US13/949,499 patent/US8748450B2/en active Active
- 2013-12-27 US US14/141,694 patent/US9072711B2/en active Active
-
2014
- 2014-06-18 JP JP2014124972A patent/JP5968953B2/ja active Active
-
2016
- 2016-07-06 JP JP2016134199A patent/JP6316881B2/ja active Active
-
2018
- 2018-03-28 JP JP2018061642A patent/JP2018115199A/ja active Pending
-
2019
- 2019-12-24 JP JP2019232665A patent/JP6864070B2/ja active Active
-
2021
- 2021-04-01 JP JP2021063101A patent/JP7177881B2/ja active Active
-
2022
- 2022-11-11 JP JP2022181010A patent/JP2023017963A/ja active Pending
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014196331A (ja) * | 2007-05-01 | 2014-10-16 | コンサート ファーマシューティカルズ インコーポレイテッド | モルフィナン化合物 |
JP2016199576A (ja) * | 2007-05-01 | 2016-12-01 | コンサート ファーマシューティカルズ インコーポレイテッド | モルフィナン化合物 |
JP2020073522A (ja) * | 2007-05-01 | 2020-05-14 | コンサート ファーマシューティカルズ インコーポレイテッド | モルフィナン化合物 |
JP2021105032A (ja) * | 2007-05-01 | 2021-07-26 | コンサート ファーマシューティカルズ インコーポレイテッド | モルフィナン化合物 |
JP7177881B2 (ja) | 2007-05-01 | 2022-11-24 | コンサート ファーマシューティカルズ インコーポレイテッド | モルフィナン化合物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7177881B2 (ja) | モルフィナン化合物 | |
US20240117407A1 (en) | Morphinan compounds | |
AU2013270618B2 (en) | Morphinan compounds | |
AU2021269403B2 (en) | Morphinan compounds | |
EP4183787A1 (en) | Morphinan compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130321 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131120 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140220 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140225 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140320 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140520 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140618 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5567048 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D04 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |